HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reaffirmed a Buy rating on TG Therapeutics (NASDAQ:TGTX) and increased the price target from $41 to $45, indicating a positive outlook on the company's stock.
January 11, 2024 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White maintains a Buy rating on TG Therapeutics and raises the price target from $41 to $45, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst typically signals a bullish outlook on the stock, which can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100